AllSci News
Definium's LSD formulation scores second Phase III win in GAD
New York-based Definium Therapeutics (Nasdaq: DFTX) reported positive topline results from the Phase III Voyage study of lysergide orally disintegrating...
BioRay moves dual-payload TROP2 ADC into the clinic
China-based BioRay Pharmaceutical Co., Ltd. has registered a first-in-human Phase I study of BR113, a dual-payload antibody-drug conjugate (ADC) targeting...
Small US biotechs cite FDA barriers to first-in-human trials: survey
Category: Clinical Trial Reform | Regulatory Body: FDA | Geography: United States | Policy Instrument: Initiative launch
Daraxonrasib study reveals resistance mechanisms in pancreatic cancer
Researchers at Redwood City, California-based Revolution Medicines and Dana-Farber Cancer Institute have published the first systematic characterization of...
Silence upsizes USD 175m offering after divesiran Phase II win
UK-based Silence Therapeutics plc (Nasdaq: SLN) announced the pricing of an upsized underwritten public offering of American Depositary Shares (ADSs),...
Beyang bags USD 30m for AI-designed retinal, leukemia drugs
Shanghai-based Beyang Therapeutics Co., Ltd. has closed an oversubscribed USD 30 million Series A financing round to advance its AI-driven drug discovery...
WuXi AppTec wins court reprieve from Pentagon military designation
A US federal court has temporarily blocked enforcement of the US Department of Defense's designation of WuXi AppTec Co., Ltd. (HKEX: 2359) on its so-called...
Laekna takes aim at Truqap as China accepts afuresertib NDA
China's drug regulator has accepted a new drug application for afuresertib, the pan-AKT inhibitor developed by Shanghai-based Laekna (HKEX: 2105.HK),...
United Labs' oral GLP-1 drug cleared for US trials
The United Laboratories International Holdings Limited (HKEX: 03933) announced on August 11 that the US FDA has cleared two investigational new drug...
Gilead refreshes ADC biomarker collab with Nucleai
Israel-based Nucleai announced an ongoing translational research collaboration with Gilead Sciences supporting Gilead's global antibody-drug conjugate (ADC)...
AbCellera offers up USD 200m in stock to support NK3 menopause antibody
Canada-based AbCellera Biologics Inc. (Nasdaq: ABCL) announced a proposed underwritten public offering of common stock and pre-funded warrants targeting USD...
Vogenx prices USD 81.3m IPO to fund SGLT1-targeted mizagliflozin
Raleigh, North Carolina-based Vogenx, Inc. (Nasdaq: VOGX), a clinical-stage biopharmaceutical company developing treatments for metabolic conditions with no...
Keymed/Belenos’s twice-yearly TSLP × IL-13 bispecific clears Phase II
China-based Keymed Biosciences Inc. (HKEX: 02162) announced that its Phase II clinical trial of CM512, a recombinant bispecific antibody targeting both...
Sentynl gains US rights to Mereo's Phase III alvelestat for alpha-1 lung disease
Mereo BioPharma (Nasdaq: MREO) and Solana Beach, California-based Sentynl Therapeutics have entered an option and license agreement granting Sentynl...
Menarini bets EUR 726m on Gan & Lee’s biweekly GLP-1
Gan & Lee Pharmaceuticals (SSE: 603087) has signed an exclusive licensing agreement with Italy-based The Menarini Group granting the European pharmaceutical...
The AllSci Brief
Free, systematic R&D and deal news. Daily.